← All trials
NCT07291037
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Jan 29, 2029
- Completion date
- Jan 29, 2029
- First posted
- Dec 18, 2025
- Last posted
- Dec 18, 2025
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Daiichi SankyoCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.